FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a pharmaceutical composition the form of an oral suspension consisting of valsartan or a pharmaceutically acceptable salt thereof and at least one or two or more ingredients specified in glycerol or a syrup or a mixture thereof, a preserving agent, a buffer system, a suspending/stabilising agent and anti-foaming agent. The buffer system is specified in sodium citrate, potassium citrate, sodium bicarbonate, sodium dihydrophosphate and potassium dihydrophosphate, and maintains pH of the composition within the range of 3.0 to 5.0. Further, the present invention refers to using the pharmaceutical composition for preparing a drug.
EFFECT: orally administered valsartan suspension provides high bioavailability and reduced variability of response to the administered dose when administered to different subjects or one subject.
10 cl, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| COMPOSITIONS IN THE FORM OF A SPRAY FOR ORAL ADMINISTRATION AND METHODS OF THE SILDENAFIL ADMINISTRATION | 2012 |
|
RU2611403C1 |
| OXICODON AND NALOXON-CONTAINING PHARMACEUTICAL COMPOSITIONS WITH INSTANT RELEASE | 2010 |
|
RU2522212C2 |
| TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
| PHARMACEUTICAL COMPOSITIONS OF KETOROLAC | 2017 |
|
RU2677663C1 |
| PHARMACEUTICAL COMPOSITIONS | 2001 |
|
RU2333757C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING HGH FOR ORAL ADMINISTRATION | 2007 |
|
RU2493868C2 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| PHARMACEUTICAL DOSAGE FORMS AND COMPOSITIONS OF COLON ABSORBED PHENYLEPHRINE | 2007 |
|
RU2454225C2 |
| GASTRO-RESISTANT DOSAGE FORMS FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE | 2018 |
|
RU2812901C2 |
